Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future Review

  


Authors: Diamond, B.; Maclachlan, K.; Chung, D. J.; Lesokhin, A. M.; Landgren, C. O.
Review Title: Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future
Abstract: With ten years of follow-up since the advent of the modern paradigm of combination induction therapy, consolidative autologous stem-cell transplant, and lenalidomide maintenance, median survival for multiple myeloma has increased to almost 50% at 10 years. Given this outlook, the overarching goal of maintenance therapy is to spare patients from the toxicities of aggressive or otherwise intrusive therapies while ideally extending survival or, at the least, extending progression-free survival or time until next treatment. This review will focus on the current landscape of maintenance therapies for multiple myeloma. The historical context and evidence for choice of agent, duration of treatment, and current strategies and ongoing trials will be discussed – as well as a focus on unmet needs. The case for studies investigating cessation of therapy and risk and response-adapted approaches will be underscored given that the current paradigm likely results in overtreatment for some patients. © 2020 Elsevier Ltd
Keywords: lenalidomide; review; treatment duration; antineoplastic agent; neoplasms; bortezomib; multiple myeloma; maintenance therapy; monoclonal antibody; minimal residual disease; carfilzomib; second primary; clinical trial (topic); pomalidomide; maintenance chemotherapy; human; priority journal; ixazomib; adaptive clinical trials
Journal Title: Best Practice and Research: Clinical Haematology
Volume: 33
Issue: 1
ISSN: 1521-6926
Publisher: Elsevier Inc.  
Date Published: 2020-03-01
Start Page: 101140
Language: English
DOI: 10.1016/j.beha.2020.101140
PUBMED: 32139006
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077919114&doi=10.1016%2fj.beha.2020.101140&partnerID=40&md5=5deb13caf3ace97cd82fdad5204410e1
Notes: Review -- Export Date: 1 April 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Alexander Meyer Lesokhin
    363 Lesokhin
  2. David Chung
    240 Chung
  3. Carl Ola Landgren
    336 Landgren
  4. Benjamin Diamond
    33 Diamond
  5. Kylee Maclachlan
    143 Maclachlan
Related MSK Work